Recent advances in reactive arthritis.
Reactive arthritis (ReA), one of the spondyloarthropathies, is an infectious related disease that occurs in a genetically predisposed individual, characterized by an immune-mediated synovitis with intra-articular persistence of viable nonculturable bacteria and/or immunogenic bacterial antigens. ReA long term prognosis is not as good as it was earlier believed. Two-thirds of patients develop prolonged joint discomfort, low back pain, or enthesopathies after acute ReA, and 15% to 30% of them develop chronic symptoms. The therapeutic options for patients with the more severe forms of the disease have been rather limited. The efficacy of tumor necrosis factor antagonists in other spondyloarthritis suggested that anticytokine therapy could also be effective for ReA. This paper reviews the latest concepts in urogenital and postenteric human leukocyte antigen-B27-associated ReA.
Colmegna
Ines
I
Espinoza
Luis R
LR
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016918:Arthritis, Reactive / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D014943:Global Health; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D015796:HLA-B27 Antigen / Q000187:drug effects / Q000276:immunology; D006801:Humans; D015994:Incidence; D000091402:Prohibitins
D000900:Anti-Bacterial Agents; D015796:HLA-B27 Antigen; C000717331:PHB2 protein, human; D000091402:Prohibitins